COLL250117P22500
- 0.60
- 0.000.00%
Collegium Pharmaceutical Newsroom
Collegium Pharmaceutical Insiders Sold US$2.3m Of Shares Suggesting Hesitancy
Collegium's Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham
Needham Upgrades Collegium Pharmaceutical(COLL.US) to Buy Rating, Announces Target Price $46
Collegium Pharmaceutical Upgraded to Buy From Hold at Needham
Needham Upgrades Collegium Pharmaceutical to Buy, Announces $46 Price Target
Express News | HC Wainwright & Co. Reiterates Buy on Collegium Pharmaceutical, Maintains $50 Price Target
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Collegium Pharmaceutical Shares Rise After 2025 Guidance
Express News | Collegium Sees 2025 Net Product Revenues $735M-$750M, Adj. EBITDA $435M-$450M
Collegium Pharma: 2025 Jornay PM Net Rev Expected to Be in Excess of $135 M >COLL
Express News | Collegium Pharmaceutical Outlook FY Adjusted Ebitda USD 435-450 Million
Press Release: Collegium Provides 2025 Financial Guidance and Business Update
Pulling Back 6.0% This Week, Collegium Pharmaceutical's NASDAQ:COLL) Three-year Decline in Earnings May Be Coming Into Investors Focus
Despite Lower Earnings Than Three Years Ago, Collegium Pharmaceutical (NASDAQ:COLL) Investors Are up 46% Since Then
Indivior CFO Steps Down From Board After Discussions With Oaktree Capital
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
US Manufacturing Index Rises To 43, Highest Since 2020
Express News | COLLEGIUM PHARMACEUTICAL Announced That Health Canada Has Approved Its Drug Jornay-PM For The Treatment Of ADHD In Children
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly
Collegium to Participate in Upcoming Investor Conferences